TY - JOUR
T1 - Comparative immunomorphology of testicular Sertoli and sertoliform tumors
AU - Mesa, Hector
AU - Gilles, Scott
AU - Datta, Milton W.
AU - Murugan, Paari
AU - Larson, Wendy
AU - Dachel, Susan
AU - Manivel, Juan C.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Sertoli cell (SC) and sertoliform tumors of the testis are very uncommon; for this reason their differential diagnosis and classification can be challenging. We applied an extensive immunophenotypic panel that included androgenic hormones, enzymes and receptors, neuroendocrine, lineage and genitourinary markers to a series of these lesions to determine if and which immunostains can aid in their diagnostic workup. Study cases included: 2 androgen insensitivity syndrome–associated SC adenomas, 3 SC tumors (SCT) not otherwise specified (SCT-NOS), 3 sclerosing SCT, 2 large cell calcifying SCT, 1 SCT with heterologous sarcomatous elements, 1 malignant SCT, and 1 sertoliform rete testis adenoma (sertoliform RTA). We found that SCT-NOS and variants with sclerosis showed a phenotype akin to atrophic seminiferous tubules characterized by gain of expression of pankeratin, calretinin, CD56, which are negative in normal SC. Distinctive phenotypes were identified in: sclerosing SCT: androgen receptors (AR) + (strong)/PAX2/PAX8+ (subset)/S100+/inhibin−; large cell calcifying SCT: calretinin+ (strong)/S100+/AR−; sertoliform RTA: PAX2/PAX8+/pankeratin+/inhibin−. Androgenic hormones and enzymes did not show diagnostic utility. A panel of calretinin, inhibin, pankeratin, S100, PAX2/PAX8, and AR consistently allowed distinction between variants of Sertoli and sertoliform tumors.
AB - Sertoli cell (SC) and sertoliform tumors of the testis are very uncommon; for this reason their differential diagnosis and classification can be challenging. We applied an extensive immunophenotypic panel that included androgenic hormones, enzymes and receptors, neuroendocrine, lineage and genitourinary markers to a series of these lesions to determine if and which immunostains can aid in their diagnostic workup. Study cases included: 2 androgen insensitivity syndrome–associated SC adenomas, 3 SC tumors (SCT) not otherwise specified (SCT-NOS), 3 sclerosing SCT, 2 large cell calcifying SCT, 1 SCT with heterologous sarcomatous elements, 1 malignant SCT, and 1 sertoliform rete testis adenoma (sertoliform RTA). We found that SCT-NOS and variants with sclerosis showed a phenotype akin to atrophic seminiferous tubules characterized by gain of expression of pankeratin, calretinin, CD56, which are negative in normal SC. Distinctive phenotypes were identified in: sclerosing SCT: androgen receptors (AR) + (strong)/PAX2/PAX8+ (subset)/S100+/inhibin−; large cell calcifying SCT: calretinin+ (strong)/S100+/AR−; sertoliform RTA: PAX2/PAX8+/pankeratin+/inhibin−. Androgenic hormones and enzymes did not show diagnostic utility. A panel of calretinin, inhibin, pankeratin, S100, PAX2/PAX8, and AR consistently allowed distinction between variants of Sertoli and sertoliform tumors.
KW - Classification
KW - Immunohistochemistry
KW - Rete testis
KW - Sertoli cell tumor
KW - Sertoli cells
KW - Testicular neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85012247076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012247076&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2016.11.004
DO - 10.1016/j.humpath.2016.11.004
M3 - Article
C2 - 27939779
AN - SCOPUS:85012247076
SN - 0046-8177
VL - 61
SP - 181
EP - 189
JO - Human pathology
JF - Human pathology
ER -